Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-06-27

Clinical Trial Update: Telotristat With Lutathera in Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial investigating telotristat with Lutathera in neuroendocrine tumors was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LUTATHERA (Lutetium Lu-177 dotatate)
  • telotristat (telotristat ethyl)

Snippet

Sponsor: Lowell Anthony, MD | Conditions: Neuroendocrine Tumors | Phase 2 | Status: TERMINATED | Results posted: 2023-06-27